AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (225 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study

Keshu Zhou1, Huijing Wu2, Xia Zhao3, Xiaohong Tan4, Xiaojing Yan5, Haisheng Liu6, Liping Su7, Yukun Lan8, Jaihui Xu8,*, Xiaohui Zhou8, Yuerong Shuang9 ( ), Huilai Zhang10 ( )
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China
Department of Oncology, Hubei Cancer Hospital, Wuhan 430079, China
Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
Department of Haematology/Oncology and Paediatric Oncology, Guangxi Medical University Affiliated Cancer Hospital, Nanning 530021, China
Department of Hematology, The First Hospital of China Medical University, Shenyang 110001, China
Department of Hematology, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang 050011, China
Department of Hematology, Shanxi Cancer Hospital Institute, Taiyuan 030013, China
Shanghai Roche Pharmaceuticals Ltd., Shanghai 201203, China
Department of Lymphatic and Hematological Oncology, Jiangxi Cancer Hospital, Nanchang 330029, China
Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

*J. Xu, formerly of Shanghai Roche Pharmaceuticals Ltd., contributed to the preparation of the manuscript.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-22-10-1218_ESM.pdf (225.6 KB)

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 22 Issue 10,
October 2025
Pages 1218-1222
DOI: 10.20892/j.issn.2095-3941.2025.0104

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Zhou K, Wu H, Zhao X, et al. Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study. Cancer Biology & Medicine, 2025, 22(10): 1218-1222. https://doi.org/10.20892/j.issn.2095-3941.2025.0104

385

Views

20

Downloads

0

Crossref

0

Web of Science

1

Scopus
Received: 08 May 2025
Accepted: 06 August 2025
Published: 30 September 2025
©2025 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License